Medical/Pharmaceuticals
Care Group Acquires Pukekohe Family Health Care to Become Largest Provider of Primary Care in East Auckland
AUCKLAND, New Zealand, Nov. 10, 2021 /PRNewswire/ -- Care Group, a renowned provider and integrator of health services, has acquired Pukekohe Family Health Care (PFHC), a large general practice based in Central Pukekohe. The latest acquisition is in sync with the group's vision to build community...
2021-11-10 21:13
3158
David C. Dvorak is THINK Surgical's New Executive Chairman of the Board of Directors
FREMONT, Calif., Nov. 10, 2021 /PRNewswire/ -- THINK Surgical, Inc., an innovator in the field of orthopedic surgical robots, today announced the appointment ofDavid C. Dvorak as the Executive Chairman of its Board of Directors. Mr. Dvorak's decades of experience in the medical device industry, ...
2021-11-10 21:00
2003
Lianhua Qingwen Sent to People for Covid-19 Containment by Cambodian Government
PHNOM PENH, Cambodia, Nov. 10, 2021 /PRNewswire/ -- On Sunday, 600 local families in Veal Veaeng District, Pursat Province,Cambodia, got Lianhua Qingwen Capsules, produced by Yiling Pharmaceutical, from Suy Sem, the Cambodian Minister of Mines and Energy, also president of the Cambodian central ...
2021-11-10 20:07
3208
LifeWave Held Amplify Summer Summit 2021
TOKYO, Nov. 10, 2021 /PRNewswire/ -- LifeWave, a U.S.-based global health technology company, hosted a summer conference onAugust 21 and 22, 2021. The conference, dubbedAmplify, focused on LifeWave's products and the company's business opportunities. It was held virtually because of recommendatio...
2021-11-10 11:18
3409
Ascletis Announces Approval of Phase II Clinical Trial of ASC22 (Envafolimab) by China NMPA for Immune Restoration/Functional Cure of HIV-1 Infected Patients
HANGZHOU, China and SHAOXING, China, Nov. 10, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces the approval of the Phase II clinical trial of ASC22 (Envafolimab) by China National Medical Products Administration (NMPA) for the proposed new indication of immune restoration/fu...
2021-11-10 08:30
4046
Smith+Nephew establishes its first Medical Education Centre for the Asia Pacific region in Singapore
LONDON, Nov. 10, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the
global medical technology business, today announces its first dedicated Medical
Education Centre to support customers across theAsia Pacific region.
2021-11-10 08:04
5970
Prenetics Announces Strong First Half 2021 Financial Results as Company Progresses Towards a U.S. Nasdaq Listing in Partnership with Artisan Acquisition Corp.
* Revenue reached US$136.5 million, up 1,039% year-over-year * Adjusted EBITDA was US$31.5 million, increased by US$34.6 million year-over-year * Prenetics has publicly filed a registration statement on Form F-4 with the SEC in connection with its proposed business combination with Artisan ...
2021-11-10 07:34
3151
INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S.
FDA Lifts Partial Clinical Hold on INNOVATE Phase 3 Segment PLYMOUTH MEETING, Pa., Nov. 9, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-a...
2021-11-09 21:00
4060
Ceres Nanosciences Establishes Nine Wastewater-based COVID-19 Surveillance Centers of Excellence Under NIH RADx Initiative
MANASSAS, Va., Nov. 9, 2021 /PRNewswire/ -- Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, is announcing the establishment of nine wastewater-based epidemiology centers of excellence, as part of theApril...
2021-11-09 20:55
3604
Regrowing Damaged Body Parts: How Osteopore, an Australian-listed Company, is Making it Accessible
SINGAPORE, Nov. 9, 2021 /PRNewswire/ -- Osteopore, an Australian and Singapore based leader in regenerative implants on a commercial scale, is developing technology that enables widespread adoption of tissue engineering. Despite the global average life expectancy rising by more than 6 years betwe...
2021-11-09 18:05
2431
Antengene to Release Preliminary Results of Selinexor for the Treatment of Peripheral T-Cell Lymphoma and NK/T-Cell Lymphoma at the 2021 ASH Annual Meeting
SHANGHAI and HONG KONG, Nov. 9, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncol...
2021-11-09 16:30
5318
Recbio Announces New Study Showing Its COVID-19 Vaccine Induced High Levels of Neutralizing Antibodies against SARS-CoV-2 and Variants of Concern
TAIZHOU, China, Nov. 9, 2021 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. ("Recbio"), a biopharmaceutical company focusing on the research, development and commercialization of innovative vaccines that can address prevalent diseases with significant burden, today announced preclinical data...
2021-11-09 10:00
4328
Sustained Hepatitis B Surface Antigen Loss in Chronic Hepatitis B Patients with Subcutaneous PD-L1 Antibody ASC22 Treatment: Interim Results of Phase IIb Study
HANGZHOU, China and SHAOXING, China, Nov. 9, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today that the interim results of 44 chronic hepatitis B (CHB) patients from a Phase IIb trial of ASC22 (Envafolimab), a subcutaneously administered PD-L1 antibody (ClinicalTrials.gov Ide...
2021-11-09 08:33
4451
CStone Pharmaceuticals and DotBio sign a global discovery collaboration and option agreement to expand emerging portfolio of next-generation innovative therapeutics
* The two sides will jointly develop up to three preclinical first-in-class or best-in-class next-generation antibody therapies, for which CStone would lead the design of the target combination based on the intended mechanism of action and DotBio will lead the design and engineering of the mole...
2021-11-09 08:05
6132
BARDA and Clarivate Partner to Identify Therapeutics Which Can Be Repurposed as Medical Countermeasures to Chemical Exposure
LONDON, Nov. 8, 2021 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced a new partnership with the Biomedical Advanced Research and Development Authority (BARDA), which provides an integra...
2021-11-08 21:00
3848
RedHill Biopharma and South Korea's Kukbo Co. Announce a Strategic Investment of Up To $10 Million in RedHill
TEL AVIV, Israel and RALEIGH, NC, Nov. 8, 2021 /PRNewswire/ -- RedHill
Biopharma Ltd.
2021-11-08 20:00
4176
RadLink, Singapore's Leading Imaging Center, Adapts Lunit AI to Analyze Chest X-rays and Mammograms
SEOUL, South Korea, Nov. 8, 2021 /PRNewswire/ -- Lunit today announced a Reference Site Agreement with RadLink, a subsidiary of the Fullerton Health Group,Singapore's leading private diagnostic and molecular imaging service provider. As a leading medical AI company, Lunit provides AI software th...
2021-11-08 14:36
4768
Ascletis and Suzhou Alphamab Expand their Partnership into Worldwide License Agreement for ASC22 (Envafolimab) to Treat Hepatitis B and Other Viral Diseases
HANGZHOU, China and SHAOXING, China and SUZHOU, China, Nov. 8, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK) and Suzhou Alphamab Co., Ltd. (Suzhou Alphamab) jointly announce today that Ascletis' subsidiary and Suzhou Alphamab have entered into an exclusive and worldwide license agreement ou...
2021-11-08 08:30
4673
Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program
SHANGHAI, Nov. 8, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inAsia, today announced that i...
2021-11-08 08:15
4070
Innovent Publishes the Preclinical Results of IBI319 (Anti PD-1/CD137 Bispecific Antibody) in Nature Communications
SAN FRANCISCO and SUZHOU, China, Nov. 8, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major di...
2021-11-08 08:00
4439
Week's Top Stories
Most Reposted
Agoda becomes first travel platform regionally to seamlessly connect with Meta's Muse
[Picked up by 294 media titles]
2026-10-28 09:00
Hong Leong Bank Strengthens Cross-Border Payment Connectivity through Partnership with UnionPay International
[Picked up by 294 media titles]
2026-10-28 12:12
Klook launches K.ai, an AI agent that manages merchants' back-office operations
[Picked up by 293 media titles]
2026-11-03 14:31
Arrowpoint Investment Partners Selects Arcesium to Scale Asia-Focused Multi-Strategy Platform
[Picked up by 280 media titles]
2026-11-03 09:00OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW
[Picked up by 277 media titles]
2026-10-28 09:00
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
55378
iQIYI Launches China's First AI Film Studio in Shanghai, with Inaugural Title "Cop in Trouble" in Production
2026-11-02 09:52
48420
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
36483
